KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Assets: 2009-2025

Historic Assets for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Sep 2025 value amounting to $40.2 billion.

  • Regeneron Pharmaceuticals' Assets rose 7.28% to $40.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $40.2 billion, marking a year-over-year increase of 7.28%. This contributed to the annual value of $37.8 billion for FY2024, which is 14.15% up from last year.
  • As of Q3 2025, Regeneron Pharmaceuticals' Assets stood at $40.2 billion, which was up 5.10% from $38.2 billion recorded in Q2 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Assets peaked at $40.2 billion during Q3 2025, and registered a low of $17.8 billion during Q1 2021.
  • Its 3-year average for Assets is $35.2 billion, with a median of $36.1 billion in 2024.
  • Data for Regeneron Pharmaceuticals' Assets shows a peak YoY skyrocketed of 48.91% (in 2021) over the last 5 years.
  • Regeneron Pharmaceuticals' Assets (Quarterly) stood at $25.4 billion in 2021, then grew by 14.86% to $29.2 billion in 2022, then climbed by 13.23% to $33.1 billion in 2023, then rose by 14.15% to $37.8 billion in 2024, then grew by 7.28% to $40.2 billion in 2025.
  • Its Assets stands at $40.2 billion for Q3 2025, versus $38.2 billion for Q2 2025 and $37.5 billion for Q1 2025.